// App-Quantinova.ai

: Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Researchers

Presenter

  • Mohamed Elmeliegy

Principal Investigators

  • Andrea Viqueira

  • Erik Vandendries

  • Anne Hickman

  • Jennifer Hibma

  • Hoi-Kei Lon

  • Joseph Piscitelli

  • Pooneh Soltantabar

  • Diane Wang

  • Sibo Jiang

  • Gregory Finn

  • Akos Czibere

Medical Centers

  • N/A

Locations

  • Spain

  • United States

Companies

  • PharmAbcine Inc.

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved